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Archaeosomes are liposomes comprised of ether lipids derived from various archaea which, as adjuvants, can 
induce robust, long-lasting humoral and cell-mediated immune responses to entrapped antigens. Traditional 
total polar lipid (TPL) archaeosome formulations are relatively complex and semi-synthetic archaeosomes 
involve many synthetic steps to arrive at the final desired glycolipid composition. We have developed a novel 
archaeosome formulation comprising a sulfated saccharide group covalently linked to the free sn-1 hydroxyl 
backbone of an archaeal core lipid (sulfated S-lactosylarchaeol, SLA) mixed with uncharged glycolipid 
(lactosylarchaeol, LA). This new class of adjuvants can be easily synthesized and retains strong 
immunostimulatory activity for induction of cell-mediated immunity following systemic immunization.  Herein, we 
demonstrate the safety of SLA/LA archaeosomes following intramuscular injection to mice and evaluate the 
immunogenicity, in vivo distribution and cellular uptake of antigen (ovalbumin) encapsulated into SLA/LA 
archaeosomes. Overall, we have found that semi-synthetic sulfated glycolipid archaeosomes are a safe and 
effective novel class of adjuvants capable of inducing strong antigen-specific immune responses in mice and 
protection against subsequent B16 melanoma tumor challenge. A key step in their mechanism of action appears 
to be the recruitment of immune cells to the injection site and the subsequent trafficking of antigen to local 
draining lymph nodes. A better understanding of the safety and mechanism of action of novel adjuvants such as 
archaeosomes is a key step in their advancement into clinical use.   
 
 
